Clinical Trials
39 trialsNCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT04880863 2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2 Completed
NCT01750281 2023-10-24
SELECT-2
AstraZeneca
Phase 2 Completed
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT00582582 2019-12-13
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT02007148 2019-02-27
MICADO
International Group of Endovascular Oncology
Phase 2 Unknown
NCT00454779 2018-10-17
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Amgen
Phase 2 Completed
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01888978 2018-04-09
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
Phase 2 Completed
NCT02793219 2017-10-30
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02793765 2017-10-30
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02474186 2017-08-03
Phase II Study for Solid Metastatic Tumors
NYU Langone Health
Phase 2 Completed
NCT02105675 2017-05-24
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT03147963 2017-05-10
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00047840 2016-08-25
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
Sanofi
Phase 2 Completed
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01703910 2015-10-09
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 2 Completed
NCT00377559 2015-10-06
MYOTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Completed
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT00697060 2015-06-24
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
AmpliMed Corporation
Phase 2 Withdrawn
NCT01069081 2015-03-06
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT00557206 2013-11-05
Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Minneapolis Veterans Affairs Medical Center
Phase 2 Terminated
NCT01038804 2013-09-18
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT00084825 2012-10-26
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00080678 2012-10-12
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00813072 2012-03-02
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
Phase 2 Completed
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00232206 2011-05-18
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
Providence Health & Services
Phase 2 Terminated
NCT00571675 2010-11-09
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Ascenta Therapeutics
Phase 2 Completed
NCT00541281 2009-10-27
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT00980603 2009-09-21
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00142038 2007-04-18
Docetaxel and Capecitabine in Advanced Gastric Cancer
Charite University, Berlin, Germany
Phase 2 Completed